17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years

I analyze 89 top Ten-Year Collected Dividend Dogs, focusing on yield-based strategies and safety via free cash flow coverage. Ten-year top dividend dogs project average net gains of 39.61% by August 2027, with risk profiles generally below market volatility. Seventeen 'safer' dogs meet the ideal of annual dividends from $1K invested exceeding share price, signaling strong income potential.

Seeking Alpha • Aug 28, 2026

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Zacks Investment Research • Aug 27, 2026

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 18, 2026

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2026

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Zacks Investment Research • Aug 6, 2026

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Viatris Reports Second-Quarter 2026 Financial Results

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn LoTM Announces Sale of Global Rights to Tyrvaya® Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Aug. 6, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results. Executive Commentary "Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business," said Scott A.

PRNewsWire • Aug 6, 2026

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).

Benzinga • Aug 6, 2026

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Zacks Investment Research • Aug 5, 2026